AKT1 and non-small cell lung carcinoma: An in vitro study showed that cobimetinib monotherapy increased Akt signaling, which is associated with a poor prognosis in NSCLC patients, while combining cobimetinib with a PI3K/mTOR inhibitor significantly reduced Akt signaling [75].